Literature DB >> 2611135

Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors.

D W Galvani1, J C Cawley.   

Abstract

The effect of alpha interferon (alpha IFN) on colony forming unit, granulocyte-macrophage (CFU-GM) formation by normal bone marrow (BM) as compared with chronic granulocytic leukaemia (CGL) BM and peripheral blood (PB) was tested in semi-solid assay systems employing either 5637CM or recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) to support growth. alpha IFN (greater than 125 U/ml) caused consistent inhibition (P = 0.02) of day-7 (late progenitor) colonies, but had little or no effect on either day-7 clusters or day-14 colonies/clusters. This selective effect on day-7 colonies was quantitatively similar for both normal and CGL (P greater than 0.5). Similar results were obtained whether or not the mononuclear preparations were depleted of potential accessory cells, suggesting that the alpha IFN-suppression is directly mediated. Morphological examination of colonies and clusters showed that IFN had no effect on cell maturation and that colony inhibition is not, therefore, a consequence of blocked maturation. Since the late-progenitor compartment is preferentially expanded in CGL, we suggest that our demonstration that alpha IFN selectively inhibits this compartment is relevant to the clinical effects of the cytokine in the disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2611135     DOI: 10.1111/j.1365-2141.1989.tb00283.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Effect of interferon-alpha on neutrophil functions.

Authors:  S Kasimir; J Brom; W König
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

2.  Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

Authors:  M Y Gordon; S B Marley; J L Lewis; R J Davidson; D X Nguyen; F H Grand; T A Amos; J M Goldman
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

3.  An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

Authors:  J J Cornelissen; R E Ploemacher; B W Wognum; A Borsboom; H C Kluin-Nelemans; A Hagemeijer; B Löwenberg
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 4.  Biotherapy of chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; F Schneller; C Huber
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

Review 5.  Role of immunotherapy in stem cell transplantation.

Authors:  Sally Arai; Hans G Klingemann
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

6.  The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies.

Authors:  J Thiele; H M Kvasnicka; N Niederle; T K Zirbes; M Schmidt; J Dammasch; B R Meuter; L D Leder; O Kloke; V Diehl
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.